Funding

HEPHAISTOS-Pharma funding news – Biotech Startup HEPHAISTOS-Pharma Secures €4.5 Million in Seed Funding

May 17, 2024 | By Startup Rise EU

French-based HEPHAISTOS-Pharma, a biotechnology company developing next generation immunotherapies against cancer targeting innate immunity to increase the cure rate of patients, secures €4.5 million seed round to finance industrialization and advance its lead candidate ONCO-Boost towards the clinic. Elaia leads a consortium previously initiated by xista science ventures, the Fondation Fournier-Majoie and Noshaq.

French-based HEPHAISTOS-Pharma, a biotechnology company developing next generation immunotherapies against cancer targeting innate immunity to increase the cure rate of patients, secures €4.5 million seed round to finance industrialization and advance its lead candidate ONCO-Boost towards the clinic. Elaia leads a consortium previously initiated by xista science ventures, the Fondation Fournier-Majoie and Noshaq.

SUMMARY

  • French-based HEPHAISTOS-Pharma, a biotechnology company developing next generation immunotherapies against cancer targeting innate immunity to increase the cure rate of patients.
  • It secures €4.5 million seed round to finance industrialization and advance its lead candidate ONCO-Boost towards the clinic.

Florian DENIS, Investment Director at Elaia, stated: “Elaia is very proud to join and strengthen the syndication. HEPHAISTOS’ core technology based on immunostimulants has the potential to turn cold tumors into hot tumors in hard-to-treat cancers. Frédéric CAROFF and his team have generated impressive preclinical data that will be scaled up towards additional value-creating milestones.”

RECOMMENDED FOR YOU

recomd
Funding
DeepJudge Funding News -DeepJudge Raises $10.7M Seed Funding Led by Coatue
Team SR
Jun 20, 2024
recomd
Funding
[Funding alert] London-based Lapse Secures €28 Million in Series A Round Funding
Startup Rise EU
Feb 28, 2024
recomd
Funding
Banktrack funding news – Spain-based Banktrack Secures €2Million Seed Funding
Startup Rise EU
May 30, 2024

Frederic CAROFF, CEO and co-founder of HEPHAISTOS-Pharma sais, “ELAIA has a proven track record in supporting biotech companies through to the clinic and success, and we are delighted to have them on board ” “With xista science ventures, Fondation Fournier-Majoie and Noshaq, our consortium of seed investors brings not only the necessary funds, but also complementary expertise and a network that will structure the company. They will play a crucial role in the success of HEPHAISTOS. ”

HEPHAISTOS’ innovative approach to innate modulation has received significant validation and support from prestigious programs, with a total of €5.8 million awarded to accelerate the development of ONCO-Boost for the treatment of hard-to-treat solid tumors, where there is a high unmet medical need, BPIFRANCE iNov national competition,

EIC Accelerator European competition and RHU clinical grant from France 2030, that will include a clinical phase 1/2 in collaboration with prestigious clinical centers.

Read also - Tulyp funding news – Paris-based Tulyp Secures €1.5 Million in Seed Funding

This seed round will mainly finance the industrialization of drug production and regulatory toxicity studies to file for the CTA in Europe. HEPHAISTOS already has a lot of preclinical data in many cancer indications, but they plan to generate new additional data in monotherapy against unmet medical needs and in combination with promising drugs from other pharmaceutical companies. Finally, it will also help to recruit new talents and complete the structuring of the board.

About HEPHAISTOS-Pharma

HEPHAISTOS-Pharma is a preclinical biotech company developing the next generation of immunostimulants against cancer, revolutionizing immune stimulation targeting innate immunity with a unique technology for intravenous administration, opening the way to metastatic and hard-to-treat indications.

HEPHAISTOS-Pharma is the laureate of prestigious grants such as Bpifrance i-Nov and the EIC accelerator in Europe. The company is also involved in the SyStInn consortium headed by academic partners that received an additional 9.8M€ grant from the French National Research Agency RHU program, which will part-fund clinical trials evaluating ONCO-Boost. HEPHAISTOS-Pharma is one of the few innovative companies to be selected for its disruptive potential and supported by the Paris Saclay Cancer Cluster.

Recommended Stories for You

story
Funding

[Funding alert] Madrid-based Gataca Raises €1.3 Million in Funding

Startup Rise EU Dec 1, 2023

story
Funding

[Funding alert] Milan-based WeRoad Secures €18 Million in Series B Round Funding

Startup Rise EU Nov 27, 2023

story
Funding

epresspack Funding News – France-based epresspack Raises €7M From Entrepreneur Invest

Team SR Jun 19, 2024

story
Funding

Aikido funding news – Security Platform Aikido Secures over €15.8 Million in Fresh Series A Round Funding

Startup Rise EU May 2, 2024

story
Funding

[Funding alert] UK-based Foodtech Startup Clean Food Group Secures €2.9 Million in Funding

Startup Rise EU Mar 27, 2024

story
Funding

[Funding alert] Pet-Wellness Company Jampy Secures €1 Million in Pre-Seed Funding

Startup Rise EU Jan 17, 2024